Provides an overview of emerging antidotes (idarucizumab, andexanet alpha, and PER977) for the reversal of target-specific oral anticoagulants.
Antidotes in trials may reduce DOAC bleeding complications; leaves open need for confirmatory efficacy and safety data.
Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.
No takes yet. Share an insight, caveat, or question.
Das et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: